Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays
QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active d...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2007-11, Vol.42 (11), p.1370-1381 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1381 |
---|---|
container_issue | 11 |
container_start_page | 1370 |
container_title | European journal of medicinal chemistry |
container_volume | 42 |
creator | Casañola-Martín, Gerardo M. Marrero-Ponce, Yovani Khan, Mahmud Tareq Hassan Ather, Arjumand Khan, Khalid M. Torrens, Francisco Rotondo, Richard |
description | QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by
k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model
Class
=
−
96.067
+
1.988
×
10
2
X0Av
+
91.907
BIC3
+
6.853
CIC1
in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The
biosilico assays and
in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound
BP4 (IC
50
=
1.72
μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC
50
=
16.67
μM) and
l-mimosine (IC
50
=
3.68
μM). These results support the role of
biosilico algorithm for the identification of new tyrosinase inhibitor compounds.
[Display omitted] |
doi_str_mv | 10.1016/j.ejmech.2007.01.026 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68543190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523407000773</els_id><sourcerecordid>68543190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo7rj6D0Ry0Vu3SSfp7ngQ1vUTFrzoOaTTlZ0aupMxyQzOvzfLDOzNU0HxvC9VDyGvOWs54_37XQu7Fdy27RgbWsZb1vVPyIYP_diITsmnZMO6TjSqE_KKvMh5xxhTPWPPyVWFxCDHfkP2n5O9j4GuULZxpj4m6jHMGO5piEdYaDmlmDHYDBTDFicsMeUP9BPW7YIuUpwhFPTobMFaZMNM4e8eEq51b5eaokcsKVKbsz3ll-SZt0uGV5d5TX5__fLr9ntz9_Pbj9ubu8YJzUrTjcICCCaVlgL0xPteSS4H7TxXk1NSeuv44LiVetS-10xCNzk9T35Wig_imrw79-5T_HOAXMyK2cGy2ADxkE0_Kim4ZhWUZ9DVR3MCb_b1dptOhjPzYNrszNm0eTBtGDfVdI29ufQfphXmx9BFbQXeXgCbnV18ssFhfuT0OErOZeU-njmoNo4IyWSHEBzMmMAVM0f8_yX_AHL-n_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68543190</pqid></control><display><type>article</type><title>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Casañola-Martín, Gerardo M. ; Marrero-Ponce, Yovani ; Khan, Mahmud Tareq Hassan ; Ather, Arjumand ; Khan, Khalid M. ; Torrens, Francisco ; Rotondo, Richard</creator><creatorcontrib>Casañola-Martín, Gerardo M. ; Marrero-Ponce, Yovani ; Khan, Mahmud Tareq Hassan ; Ather, Arjumand ; Khan, Khalid M. ; Torrens, Francisco ; Rotondo, Richard</creatorcontrib><description>QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by
k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model
Class
=
−
96.067
+
1.988
×
10
2
X0Av
+
91.907
BIC3
+
6.853
CIC1
in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The
biosilico assays and
in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound
BP4 (IC
50
=
1.72
μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC
50
=
16.67
μM) and
l-mimosine (IC
50
=
3.68
μM). These results support the role of
biosilico algorithm for the identification of new tyrosinase inhibitor compounds.
[Display omitted]</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2007.01.026</identifier><identifier>PMID: 17637486</identifier><identifier>CODEN: EJMCA5</identifier><language>eng</language><publisher>Oxford: Elsevier Masson SAS</publisher><subject>Biological and medical sciences ; Bipiperidine series ; Computational Biology ; Computer Simulation ; Databases, Factual ; Discriminant Analysis ; Dragon descriptor ; Drug Design ; LDA-based QSAR model ; Ligands ; Medical sciences ; Peptides - analysis ; Peptides - chemistry ; Peptides - classification ; Peptides - pharmacology ; Pharmacology. Drug treatments ; Piperidines - chemistry ; Piperidines - pharmacology ; Quantitative Structure-Activity Relationship ; Reproducibility of Results ; Skin, nail, hair, dermoskeleton ; Software ; Tyrosinase inhibitor ; Virtual screening</subject><ispartof>European journal of medicinal chemistry, 2007-11, Vol.42 (11), p.1370-1381</ispartof><rights>2007 Elsevier Masson SAS</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</citedby><cites>FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2007.01.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19884114$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17637486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casañola-Martín, Gerardo M.</creatorcontrib><creatorcontrib>Marrero-Ponce, Yovani</creatorcontrib><creatorcontrib>Khan, Mahmud Tareq Hassan</creatorcontrib><creatorcontrib>Ather, Arjumand</creatorcontrib><creatorcontrib>Khan, Khalid M.</creatorcontrib><creatorcontrib>Torrens, Francisco</creatorcontrib><creatorcontrib>Rotondo, Richard</creatorcontrib><title>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by
k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model
Class
=
−
96.067
+
1.988
×
10
2
X0Av
+
91.907
BIC3
+
6.853
CIC1
in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The
biosilico assays and
in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound
BP4 (IC
50
=
1.72
μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC
50
=
16.67
μM) and
l-mimosine (IC
50
=
3.68
μM). These results support the role of
biosilico algorithm for the identification of new tyrosinase inhibitor compounds.
[Display omitted]</description><subject>Biological and medical sciences</subject><subject>Bipiperidine series</subject><subject>Computational Biology</subject><subject>Computer Simulation</subject><subject>Databases, Factual</subject><subject>Discriminant Analysis</subject><subject>Dragon descriptor</subject><subject>Drug Design</subject><subject>LDA-based QSAR model</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Peptides - analysis</subject><subject>Peptides - chemistry</subject><subject>Peptides - classification</subject><subject>Peptides - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - chemistry</subject><subject>Piperidines - pharmacology</subject><subject>Quantitative Structure-Activity Relationship</subject><subject>Reproducibility of Results</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Software</subject><subject>Tyrosinase inhibitor</subject><subject>Virtual screening</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoMo7rj6D0Ry0Vu3SSfp7ngQ1vUTFrzoOaTTlZ0aupMxyQzOvzfLDOzNU0HxvC9VDyGvOWs54_37XQu7Fdy27RgbWsZb1vVPyIYP_diITsmnZMO6TjSqE_KKvMh5xxhTPWPPyVWFxCDHfkP2n5O9j4GuULZxpj4m6jHMGO5piEdYaDmlmDHYDBTDFicsMeUP9BPW7YIuUpwhFPTobMFaZMNM4e8eEq51b5eaokcsKVKbsz3ll-SZt0uGV5d5TX5__fLr9ntz9_Pbj9ubu8YJzUrTjcICCCaVlgL0xPteSS4H7TxXk1NSeuv44LiVetS-10xCNzk9T35Wig_imrw79-5T_HOAXMyK2cGy2ADxkE0_Kim4ZhWUZ9DVR3MCb_b1dptOhjPzYNrszNm0eTBtGDfVdI29ufQfphXmx9BFbQXeXgCbnV18ssFhfuT0OErOZeU-njmoNo4IyWSHEBzMmMAVM0f8_yX_AHL-n_I</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Casañola-Martín, Gerardo M.</creator><creator>Marrero-Ponce, Yovani</creator><creator>Khan, Mahmud Tareq Hassan</creator><creator>Ather, Arjumand</creator><creator>Khan, Khalid M.</creator><creator>Torrens, Francisco</creator><creator>Rotondo, Richard</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</title><author>Casañola-Martín, Gerardo M. ; Marrero-Ponce, Yovani ; Khan, Mahmud Tareq Hassan ; Ather, Arjumand ; Khan, Khalid M. ; Torrens, Francisco ; Rotondo, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-283aee3045943e9b166541479cf15bc544fac17c1a4989f6904e2bc9dbfd55173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Bipiperidine series</topic><topic>Computational Biology</topic><topic>Computer Simulation</topic><topic>Databases, Factual</topic><topic>Discriminant Analysis</topic><topic>Dragon descriptor</topic><topic>Drug Design</topic><topic>LDA-based QSAR model</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Peptides - analysis</topic><topic>Peptides - chemistry</topic><topic>Peptides - classification</topic><topic>Peptides - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - chemistry</topic><topic>Piperidines - pharmacology</topic><topic>Quantitative Structure-Activity Relationship</topic><topic>Reproducibility of Results</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Software</topic><topic>Tyrosinase inhibitor</topic><topic>Virtual screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casañola-Martín, Gerardo M.</creatorcontrib><creatorcontrib>Marrero-Ponce, Yovani</creatorcontrib><creatorcontrib>Khan, Mahmud Tareq Hassan</creatorcontrib><creatorcontrib>Ather, Arjumand</creatorcontrib><creatorcontrib>Khan, Khalid M.</creatorcontrib><creatorcontrib>Torrens, Francisco</creatorcontrib><creatorcontrib>Rotondo, Richard</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casañola-Martín, Gerardo M.</au><au>Marrero-Ponce, Yovani</au><au>Khan, Mahmud Tareq Hassan</au><au>Ather, Arjumand</au><au>Khan, Khalid M.</au><au>Torrens, Francisco</au><au>Rotondo, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>42</volume><issue>11</issue><spage>1370</spage><epage>1381</epage><pages>1370-1381</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><coden>EJMCA5</coden><abstract>QSAR (quantitative structure–activity relationship) studies of tyrosinase inhibitors employing Dragon descriptors and linear discriminant analysis (LDA) are presented here. A data set of 653 compounds, 245 with tyrosinase inhibitory activity and 408 having other clinical uses were used. The active data set was processed by
k-means cluster analysis in order to design training and prediction series. Seven LDA-based QSAR models were obtained. The discriminant functions applied showed a globally good classification of 99.79% for the best model
Class
=
−
96.067
+
1.988
×
10
2
X0Av
+
91.907
BIC3
+
6.853
CIC1
in the training set. External validation processes to assess the robustness and predictive power of the obtained model were carried out. This external prediction set had an accuracy of 99.44%. After that, the developed models were used in ligand-based virtual screening of tyrosinase inhibitors from the literature and never considered in either training or predicting series. In this case, all screened chemicals were correctly classified by the LDA-based QSAR models. As a final point, these fitted models were used in the screening of new bipiperidine series as new tyrosinase inhibitors. These methods are an adequate alternative to the process of selection/identification of new bioactive compounds. The
biosilico assays and
in vitro results of inhibitory activity on mushroom tyrosinase showed good correspondence. It is important to stand out that compound
BP4 (IC
50
=
1.72
μM) showed higher activity in the inhibition against the enzyme than reference compound kojic acid (IC
50
=
16.67
μM) and
l-mimosine (IC
50
=
3.68
μM). These results support the role of
biosilico algorithm for the identification of new tyrosinase inhibitor compounds.
[Display omitted]</abstract><cop>Oxford</cop><pub>Elsevier Masson SAS</pub><pmid>17637486</pmid><doi>10.1016/j.ejmech.2007.01.026</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2007-11, Vol.42 (11), p.1370-1381 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_68543190 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Biological and medical sciences Bipiperidine series Computational Biology Computer Simulation Databases, Factual Discriminant Analysis Dragon descriptor Drug Design LDA-based QSAR model Ligands Medical sciences Peptides - analysis Peptides - chemistry Peptides - classification Peptides - pharmacology Pharmacology. Drug treatments Piperidines - chemistry Piperidines - pharmacology Quantitative Structure-Activity Relationship Reproducibility of Results Skin, nail, hair, dermoskeleton Software Tyrosinase inhibitor Virtual screening |
title | Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A50%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dragon%20method%20for%20finding%20novel%20tyrosinase%20inhibitors:%20Biosilico%20identification%20and%20experimental%20in%20vitro%20assays&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Casa%C3%B1ola-Mart%C3%ADn,%20Gerardo%20M.&rft.date=2007-11-01&rft.volume=42&rft.issue=11&rft.spage=1370&rft.epage=1381&rft.pages=1370-1381&rft.issn=0223-5234&rft.eissn=1768-3254&rft.coden=EJMCA5&rft_id=info:doi/10.1016/j.ejmech.2007.01.026&rft_dat=%3Cproquest_cross%3E68543190%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68543190&rft_id=info:pmid/17637486&rft_els_id=S0223523407000773&rfr_iscdi=true |